Asia
Amgen reunites with Kyowa Kirin on the development and potential commercialization of KHK4083, an atopic dermatitis drug, which impacts nearly 30 million people worldwide.
The latest news in COVID-19 includes support for an investigation into the origins of the virus, a new naming system, and legal discussions of whether employers can mandate vaccination.
The funds will enable Esco that provides life sciences tools and services, to expand its toehold in China and the United States.
Companies continue to report promising data for vaccines and therapies against COVID-19. Here’s a look.
Drug development requires solid funding. Here’s who’s standing on higher ground this week with fresh investment dollars.
Engine is ready to drive its lead program into clinical trials by 2023 while Giiant’s preclinical program will target moderate-to-severe ulcerative colitis.
The purpose is to develop cell-based disease models to accelerate drug discovery and reduce development costs.
The disclosure comes the day before the WHO is expected to plan for the next phase of investigations into the origins of COVID-19.
Wang, who has played a key role in the development of more than 25 innovative medicines at Eli Lilly and GlaxoSmithKline, made him the ideal fit for the company’s next chapter.
If approved, Takeda said Maribavir would become the first and only treatment indicated for CMV infection in refractory patients.
PRESS RELEASES